Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

X
Trial Profile

Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aumolertinib (Primary) ; Bevacizumab; Pemetrexed
  • Indications Adenocarcinoma; Brain metastases; Lung cancer; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2022 Results (n=10; Form Feb 2020 to Nov 2021; data cutoff date Nov 30, 2021) assessing the efficacy and safety of aumolertinib plus bevacizumab and pemetrexed in first-line treatment of patients with EGFRm non-small cell lung cancer and brain metastasis, presented at the 2022 World Conference on Lung Cancer.
    • 02 Dec 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top